ALIEN-WORLDS
28.3.2022 15:11:05 CEST | Business Wire | Press release
Minecraft , the best-selling video game in history engaging more than 170 million players, will be able to earn Trilium, the native cryptocurrency in the Alien Worlds metaverse. Alien Worlds is one of the largest play to earn (P2E) blockchain games and NFT metaverse.
Launched in 2020, Alien Worlds has grown to be the second largest blockchain platform by monthly active users. In the game, users can play with unique digital items (NFTs), stake Trilium tokens, travel on Alien Worlds Missions to other planets, vote in elections, and run for planetary council. The game’s 6 planet DAOs compete with each other for Trilium, encouraging user collaboration.
The new interoperability bridge to the world’s longest running and most popular online building platform will have resounding effects in the traditional and blockchain gaming worlds. The bridge will accelerate the onboarding of non-blockchain gamers onto the Alien Worlds metaverse, and also due to the open sourced nature of the code developed - empower other Minecraft servers to earn play-to-earn rewards. Plus, it will allow other blockchain projects to tap into Minecraft's vast user base.
Additionally, this interoperability will offer traditional gamers the opportunity to earn assets, in this case Trilium, and soon NFTs, for completing quests. Players are able to exchange their digital assets freely, enabling them to earn real world utility by getting involved in Alien Worlds’ simulated economy.
“This bridge is significant in that we are linking one of the world’s most popular decentralized games to the blockchain, and opening up a world of new possibilities for Minecraft players through our social metaverse,” says Alien Worlds co-founder Saro McKenna. “We think our combination of economics, team strategy and earning will convert Minecraft players of all ages into Web3 players.”
Additionally, earning Trilium will allow Minecraft gamers to stake the fungible token to one of the Alien Worlds Planet DAOs, which hold some of the largest treasuries in the space. Staked Trilium translates into voting power to determine control of planetary treasuries. Minecraft players will not only be able to learn about DAOs, but also to participate in the collaborative, competitive and highly strategic environment that their gamification entails.
About Alien Worlds
Alien Worlds is a breakthrough NFT Metaverse and one of the world’s most popular play-to-earn blockchain games, where users can play with unique digital assets (NFTs), stake Trilium tokens, travel on Missions to the planets, vote in elections, and run for planetary council. The game’s 6 planet DAOs compete with each other for Trilium, allowing users to collaborate, compete and strategize with one another.
With almost 7 million all-time players and more than 700,000 Monthly Active Users (number of unique wallet addresses interacting with Alien Worlds' smart contracts on a monthly basis, DappRadar ), Alien Worlds has rapidly climbed the DappRadar ranking charts and inspired individuals to scale new heights of imagination in order to create, share and thrive in the Social Metaverse.
To access and play Alien Worlds and the new Alien Worlds Missions game, visit www.alienworlds.io , play.alienworlds.io/missions and the Explorers Station .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005182/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom